Characteristics of study population (n = 7969) from 97 studies
| . | Data . | Studies reporting the variable, n . |
|---|---|---|
| Patients characteristics | ||
| Age, mean (SD), years | 49.2 ± 10.3 | 91 |
| Male sex, n/N (%) | 4404/7886 (55.8) | 95 |
| Site of SVT | ||
| Portal vein thrombosis, n/N (%) | 3365/6192 (54.3) | 63 |
| Mesenteric vein thrombosis, n/N (%) | 1015/4271 (23.8) | 35 |
| Splenic vein thrombosis, n/N (%) | 452/3570 (12.7) | 18 |
| Budd-Chiari syndrome, n/N (%) | 1153/3624 (31.8) | 25 |
| Multiple sites thrombosis, n/N (%) | 2297/5937 (38.7) | 64 |
| Not reported, n/N (%) | 55/220 (25.0) | 6 |
| Vein involvement | ||
| Partial, n/N (%) | 521/853 (61.1) | 20 |
| Complete, n/N (%) | 306/853 (35.9) | 20 |
| Not reported, n/N (%) | 26/853 (3.0) | 20 |
| Stage of thrombosis | ||
| Acute/recent, n/N (%) | 2607/3424 (76.1) | 57 |
| Chronic, n/N (%) | 770/3424 (22.5) | 57 |
| Not reported, n/N (%) | 47/3424 (1.4) | 57 |
| Risk factors | ||
| Liver cirrhosis, n/N (%) | 2578/5518 (46.7) | 51 |
| Myeloproliferative neoplasm, n/N (%) | 1429/4598 (31.1) | 43 |
| Unprovoked, n/N (%) | 770/3070 (25.1) | 35 |
| Solid cancer, n/N (%) | 1108/4787 (23.1) | 42 |
| Surgery, n/N (%) | 642/3762 (17.1) | 44 |
| Abdominal inflammation/infection, n/N (%) | 726/4346 (16.7) | 41 |
| Hormonal replacement therapy, n/N (%) | 297/3250 (9.1) | 31 |
| Thrombophilia | ||
| JAK2 V617F, n positive/N tested (%) | 148/802 (18.5) | 9 |
| Antiphospholipid syndrome, n positive/N tested (%) | 135/1064 (12.7) | 20 |
| Factor V Leiden mutation, n positive/N tested (%) | 224/1938 (11.6) | 28 |
| Protein C and/or S deficiency, n positive/N tested (%) | 125/1085 (11.5) | 21 |
| Prothrombin G2021A mutation, n positive/N tested (%) | 112/1257 (8.9) | 15 |
| Antithrombin-III deficiency, n positive/N tested (%) | 30/904 (3.3) | 13 |
| Diagnosis of SVT | ||
| Computed tomography, n/N (%) | 3418/4973 (68.7) | 56 |
| Doppler ultrasonography, n/N (%) | 1794/4645 (38.6) | 49 |
| Angiography, n/N (%) | 265/2627 (10.1) | 16 |
| Magnetic resonance imaging, n/N (%) | 297/3633 (8.2) | 24 |
| Perioperative, n/N (%) | 153/2378 (6.4) | 13 |
| Follow-up imaging | ||
| Ultrasonography, n/N (%) | 484/494 (98.0) | 13 |
| Computed tomography, n/N (%) | 507/678 (74.8) | 16 |
| Median follow-up, mo | 28.6 (6 to 144) | 62 |
| Parenteral anticoagulation | ||
| LMWH, n/N (%) | 1038/2365 (43.9) | 24 |
| LMWH or UFH, n/N (%) | 383/1785 (21.5) | 13 |
| Fondaparinux, n/N (%) | 26/703 (3.7) | 2 |
| Oral anticoagulation | ||
| LMWH→VKAs, n/N (%) | 1320/2672 (49.4) | 40 |
| VKAs, n/N (%) | 1892/5170 (36.6) | 39 |
| DOACs, n/N (%) | 142/1125 (12.6) | 9 |
| Antiplatelet therapy | 189/2569 (7.4) | 15 |
| Mixed strategies, n/N (%) | 505/1817 (27.8) | 22 |
| No anticoagulation, n/N (%) | 1424/5416 (26.3) | 66 |
| Systemic or catheter directed thrombolysis, n/N (%) | 207/2477 (8.4) | 25 |
| Median treatment duration, months | 8.4 (0.4 to 108) | 36 |
| Other therapeutic procedures | ||
| Thrombectomy/stenting, n/N (%) | 176/1656 (10.6) | 16 |
| TIPS, n/N (%) | 482/2960 (16.3) | 26 |
| Liver transplantation, n/N (%) | 191/1634 (11.7) | 20 |
| Surgery, n/N (%) | 154/1259 (12.2) | 20 |
| . | Data . | Studies reporting the variable, n . |
|---|---|---|
| Patients characteristics | ||
| Age, mean (SD), years | 49.2 ± 10.3 | 91 |
| Male sex, n/N (%) | 4404/7886 (55.8) | 95 |
| Site of SVT | ||
| Portal vein thrombosis, n/N (%) | 3365/6192 (54.3) | 63 |
| Mesenteric vein thrombosis, n/N (%) | 1015/4271 (23.8) | 35 |
| Splenic vein thrombosis, n/N (%) | 452/3570 (12.7) | 18 |
| Budd-Chiari syndrome, n/N (%) | 1153/3624 (31.8) | 25 |
| Multiple sites thrombosis, n/N (%) | 2297/5937 (38.7) | 64 |
| Not reported, n/N (%) | 55/220 (25.0) | 6 |
| Vein involvement | ||
| Partial, n/N (%) | 521/853 (61.1) | 20 |
| Complete, n/N (%) | 306/853 (35.9) | 20 |
| Not reported, n/N (%) | 26/853 (3.0) | 20 |
| Stage of thrombosis | ||
| Acute/recent, n/N (%) | 2607/3424 (76.1) | 57 |
| Chronic, n/N (%) | 770/3424 (22.5) | 57 |
| Not reported, n/N (%) | 47/3424 (1.4) | 57 |
| Risk factors | ||
| Liver cirrhosis, n/N (%) | 2578/5518 (46.7) | 51 |
| Myeloproliferative neoplasm, n/N (%) | 1429/4598 (31.1) | 43 |
| Unprovoked, n/N (%) | 770/3070 (25.1) | 35 |
| Solid cancer, n/N (%) | 1108/4787 (23.1) | 42 |
| Surgery, n/N (%) | 642/3762 (17.1) | 44 |
| Abdominal inflammation/infection, n/N (%) | 726/4346 (16.7) | 41 |
| Hormonal replacement therapy, n/N (%) | 297/3250 (9.1) | 31 |
| Thrombophilia | ||
| JAK2 V617F, n positive/N tested (%) | 148/802 (18.5) | 9 |
| Antiphospholipid syndrome, n positive/N tested (%) | 135/1064 (12.7) | 20 |
| Factor V Leiden mutation, n positive/N tested (%) | 224/1938 (11.6) | 28 |
| Protein C and/or S deficiency, n positive/N tested (%) | 125/1085 (11.5) | 21 |
| Prothrombin G2021A mutation, n positive/N tested (%) | 112/1257 (8.9) | 15 |
| Antithrombin-III deficiency, n positive/N tested (%) | 30/904 (3.3) | 13 |
| Diagnosis of SVT | ||
| Computed tomography, n/N (%) | 3418/4973 (68.7) | 56 |
| Doppler ultrasonography, n/N (%) | 1794/4645 (38.6) | 49 |
| Angiography, n/N (%) | 265/2627 (10.1) | 16 |
| Magnetic resonance imaging, n/N (%) | 297/3633 (8.2) | 24 |
| Perioperative, n/N (%) | 153/2378 (6.4) | 13 |
| Follow-up imaging | ||
| Ultrasonography, n/N (%) | 484/494 (98.0) | 13 |
| Computed tomography, n/N (%) | 507/678 (74.8) | 16 |
| Median follow-up, mo | 28.6 (6 to 144) | 62 |
| Parenteral anticoagulation | ||
| LMWH, n/N (%) | 1038/2365 (43.9) | 24 |
| LMWH or UFH, n/N (%) | 383/1785 (21.5) | 13 |
| Fondaparinux, n/N (%) | 26/703 (3.7) | 2 |
| Oral anticoagulation | ||
| LMWH→VKAs, n/N (%) | 1320/2672 (49.4) | 40 |
| VKAs, n/N (%) | 1892/5170 (36.6) | 39 |
| DOACs, n/N (%) | 142/1125 (12.6) | 9 |
| Antiplatelet therapy | 189/2569 (7.4) | 15 |
| Mixed strategies, n/N (%) | 505/1817 (27.8) | 22 |
| No anticoagulation, n/N (%) | 1424/5416 (26.3) | 66 |
| Systemic or catheter directed thrombolysis, n/N (%) | 207/2477 (8.4) | 25 |
| Median treatment duration, months | 8.4 (0.4 to 108) | 36 |
| Other therapeutic procedures | ||
| Thrombectomy/stenting, n/N (%) | 176/1656 (10.6) | 16 |
| TIPS, n/N (%) | 482/2960 (16.3) | 26 |
| Liver transplantation, n/N (%) | 191/1634 (11.7) | 20 |
| Surgery, n/N (%) | 154/1259 (12.2) | 20 |
TIPS, transjugular intrahepatic portosystemic shunt; UFH, unfractionated heparin.